[go: up one dir, main page]

CY1119865T1 - Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον - Google Patents

Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον

Info

Publication number
CY1119865T1
CY1119865T1 CY20181100112T CY181100112T CY1119865T1 CY 1119865 T1 CY1119865 T1 CY 1119865T1 CY 20181100112 T CY20181100112 T CY 20181100112T CY 181100112 T CY181100112 T CY 181100112T CY 1119865 T1 CY1119865 T1 CY 1119865T1
Authority
CY
Cyprus
Prior art keywords
treatment
pharmaceutical compositions
disease
parkinson
compounds
Prior art date
Application number
CY20181100112T
Other languages
English (en)
Inventor
Itschak Lamensdorf
Yoram Sela
Original Assignee
Pharma Two B Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119865(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Two B Ltd. filed Critical Pharma Two B Ltd.
Publication of CY1119865T1 publication Critical patent/CY1119865T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Παρέχονται φαρμακευτικές συνθέσεις για την αντιμετώπιση της νόσου του Πάρκινσον, οι οποίες περιλαμβάνουν έναν φαρμακευτικώς αποδεκτό φορέα και έναν συνδυασμό σταθερής δόσης δύο δραστικών παραγόντων που επιλέγονται από ενώσεις που έχουν είτε νευροπροστατευτικά ή συμπτωματικά αποτελέσματα, ή και τα δύο, σε παρκινσονικούς ασθενείς, όπου η γραμμομοριακή αναλογία των δύο ενώσεων είναι στο εύρος από 1:1 έως 1:100. Οι συνθέσεις μορφοποιούνται για άμεση απελευθέρωση, ελεγχόμενη απελευθέρωση, ή και άμεση και ελεγχόμενη απελευθέρωση.
CY20181100112T 2008-06-06 2018-01-31 Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον CY1119865T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5932608P 2008-06-06 2008-06-06
PCT/IL2009/000567 WO2009147681A1 (en) 2008-06-06 2009-06-07 Pharmaceutical compositions for treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
CY1119865T1 true CY1119865T1 (el) 2018-06-27

Family

ID=41051156

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100112T CY1119865T1 (el) 2008-06-06 2018-01-31 Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον

Country Status (22)

Country Link
US (2) US8969417B2 (el)
EP (1) EP2303330B2 (el)
JP (1) JP5648216B2 (el)
KR (1) KR101613749B1 (el)
CN (1) CN102105169B (el)
AU (1) AU2009254730B2 (el)
BR (1) BRPI0914902B8 (el)
CA (1) CA2726833C (el)
CL (1) CL2010001358A1 (el)
CY (1) CY1119865T1 (el)
DK (1) DK2303330T4 (el)
ES (1) ES2659394T5 (el)
HU (1) HUE037974T2 (el)
LT (1) LT2303330T (el)
MX (1) MX2010013393A (el)
NO (1) NO2303330T3 (el)
NZ (1) NZ590291A (el)
PL (1) PL2303330T5 (el)
PT (1) PT2303330T (el)
RU (1) RU2540470C9 (el)
WO (1) WO2009147681A1 (el)
ZA (1) ZA201100034B (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2531181T (lt) 2010-02-03 2019-07-10 Pharma Two B Ltd. Rasagilino uždelsto atpalaidavimo kompozicijos ir jų panaudojimas
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
RU2642962C9 (ru) 2012-01-12 2018-05-04 Фарма Ту Б Лтд. Терапия болезни паркинсона с применением комбинации с фиксированными дозами
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
WO2013168032A1 (en) * 2012-05-07 2013-11-14 Micro Labs Limited Pharmaceutical compositions comprising rasagiline
KR101320945B1 (ko) * 2012-07-03 2013-10-23 주식회사파마킹 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
CN104768545A (zh) * 2012-09-27 2015-07-08 泰华制药工业有限公司 雷沙吉兰和普多比啶组合以治疗神经退化性病症,尤其亨廷顿氏病
BR112015022896B1 (pt) 2013-03-15 2022-08-23 Chongxi Yu Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson
EP2808023A1 (en) * 2013-05-30 2014-12-03 Université Pierre et Marie Curie (Paris 6) New drug for the treatment and/or prevention of depressive disorders
CN104473942A (zh) * 2014-12-12 2015-04-01 青岛大学 一种抗帕金森氏病的药物组合物
JP6853791B2 (ja) 2015-05-26 2021-03-31 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー パーキンソン病及び関連する障害の治療における使用のための組成物
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
US20190343780A1 (en) * 2016-12-22 2019-11-14 Rvx Therapeutics Ltd. Low dose drug combinations for use in preventing and treating neuronal damage
WO2019010491A1 (en) * 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
JP6596483B2 (ja) * 2017-12-28 2019-10-23 テックフィールズ ファーマ カンパニー リミテッド パ−キンソン病治療用の新規高透過薬物及びその組成物
WO2020084168A1 (en) * 2018-10-26 2020-04-30 Icm (Institut Du Cerveau Et De La Moelle Épinière) Tetracycline compound for treating drug-induced dyskinesia
US11701340B2 (en) * 2019-04-17 2023-07-18 Vici Health Sciences., Llc Liquid pharmaceutical compositions
WO2020227646A1 (en) * 2019-05-09 2020-11-12 Apkarian Technologies Llc Methods and compositions for treating pain
JP2023504876A (ja) * 2019-12-06 2023-02-07 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 薬物組成物、キット及びその応用
US11896573B2 (en) 2020-07-24 2024-02-13 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
US12084491B2 (en) 2020-09-10 2024-09-10 Prothena Biosciences Limited Treatment of Parkinson's disease
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
CN114762684B (zh) * 2021-01-14 2023-11-21 华益泰康药业股份有限公司 一种治疗帕金森的缓释胶囊及其制备方法
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
KR20240080457A (ko) * 2022-11-30 2024-06-07 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3764144D1 (de) 1986-04-16 1990-09-13 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
EP0828513B1 (en) * 1995-05-26 2004-01-21 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective nmda antagonists
JP2004500425A (ja) 2000-04-19 2004-01-08 リリー　アイコス　リミテッド　ライアビリティ　カンパニー パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
US20070225379A1 (en) 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
FR2857594B1 (fr) * 2003-07-17 2005-09-16 Servier Lab Composition pharmaceutique pour l'administration par voie nasale de piribedil
US20090017015A1 (en) 2004-02-20 2009-01-15 Thomas Edward Hughes Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
WO2007002518A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
US20090325911A1 (en) 2005-10-21 2009-12-31 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of Androgens for the Treatment of Parkinson's Disease
DE602006018529D1 (de) † 2005-12-29 2011-01-05 Osmotica Kereskedelmi Es Szolgaltato Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
BRPI0708071A8 (pt) 2006-02-17 2017-12-26 Birds Pharma Gmbh Berolina Innovative Res & Development Services Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
MX2008012781A (es) 2006-04-03 2008-10-14 Teva Pharma Uso de rasagilina para el tratamiento de sindrome de piernas inquietas.
CN102160865A (zh) * 2006-05-16 2011-08-24 诺普神经科学股份有限公司 R(+)和s(-)普拉克索的组合物以及使用该组合物的方法
JP5539717B2 (ja) 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
TW200820963A (en) 2006-07-28 2008-05-16 Xenoport Inc Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
CA2661220A1 (en) 2006-08-21 2008-02-28 James R. Hauske Multimediator transporter inhibitors for use in treatment of central nervous system disorders
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
TWI381838B (zh) 2006-11-01 2013-01-11 Purdue Pharma Lp 苯基丙醯胺化合物及其應用
US20100092554A1 (en) † 2007-04-24 2010-04-15 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
RU2540470C2 (ru) 2015-02-10
MX2010013393A (es) 2011-06-21
BRPI0914902B8 (pt) 2022-04-12
BRPI0914902B1 (pt) 2022-02-22
NZ590291A (en) 2013-11-29
AU2009254730B2 (en) 2014-06-26
RU2540470C9 (ru) 2015-07-20
LT2303330T (lt) 2018-04-10
DK2303330T4 (da) 2021-09-13
PL2303330T5 (pl) 2021-10-25
PT2303330T (pt) 2018-02-12
DK2303330T3 (en) 2018-02-26
PL2303330T3 (pl) 2018-04-30
CA2726833C (en) 2016-03-22
US20150133513A1 (en) 2015-05-14
KR101613749B1 (ko) 2016-04-19
ES2659394T5 (es) 2021-12-13
HUE037974T2 (hu) 2018-09-28
KR20110031181A (ko) 2011-03-24
EP2303330B2 (en) 2021-06-16
US20110230513A1 (en) 2011-09-22
US9259418B2 (en) 2016-02-16
ZA201100034B (en) 2012-04-25
CL2010001358A1 (es) 2011-08-19
NO2303330T3 (el) 2018-04-14
CN102105169B (zh) 2014-09-10
WO2009147681A1 (en) 2009-12-10
RU2010154716A (ru) 2012-08-10
JP5648216B2 (ja) 2015-01-07
CA2726833A1 (en) 2009-12-10
BRPI0914902A2 (pt) 2017-06-20
US8969417B2 (en) 2015-03-03
JP2011522035A (ja) 2011-07-28
EP2303330A1 (en) 2011-04-06
CN102105169A (zh) 2011-06-22
ES2659394T3 (es) 2018-03-15
AU2009254730A1 (en) 2009-12-10
EP2303330B1 (en) 2017-11-15

Similar Documents

Publication Publication Date Title
CY1119865T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον
HK1116073A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
CY1110990T1 (el) Παραγωγα αδενοσινης ως αγωνιστες υποδοχεων α2α
CY1113323T1 (el) Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
CY1111433T1 (el) Φαρμακευτικο τυποποιημενο παρασκευασμα δεσιταβινης
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
CY1110952T1 (el) Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3
CY1113846T1 (el) Παραγωγα πυριμιδινης για την θεραπευτικη αντιμετωπιση του ασθματος, copd, αλλεργικης ρινιτιδας, αλλεργικης επιπεφυκιτιδας, ατοπικης δερματιτιδας, καρκινου, ηπατιτιδας β, ηπατιτιδας c, hiv, hpv, βακτηριακων λοιμωξεων και δερματωσης
TW200638935A (en) Pyridazine derivatives and their use as therapeutic agents
ECSP055867A (es) Derivados de pirrolopirimidina
UY29868A1 (es) Nucleocidos 4 modificados como agentes antivirales
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.